ESTELA‐Study: Long‐Term Effectiveness and Safety of Anti‐Calcitonin Gene‐Related Peptide Monoclonal Antibodies in Real‐World Clinical Practice
Open Access
- 25 June 2026
- journal article
- research article
- Published by Wiley in Brain and Behavior
- Vol. 16 (6) , e71560
Abstract
Background: Anti‐CGRP antibodies are effective and safe in real‐world migraine management, but guidelines recommend discontinuation after 12–18 months due to limited long‐term data and remaining uncertainties regarding optimal treatment duration and sustained safety, highlighting the need for large‐scale long‐term real‐world evidence. This study evaluated their safety and effectiveness in patients treated for ≥2 years. Methods: This multicenter retrospective study included patients from 13 headache units who received the same anti‐CGRP antibody for ≥24 months, excluding discontinuation periods. Baseline characteristics, monthly headache days (MHD), monthly migraine days (MMD), and adverse events (AEs) were recorded at baseline, 6 months, 1, 2, 3, and 4 years. Descriptive statistics were used to summarize clinical characteristics, and appropriate parametric or non‐parametric tests were applied for group comparisons. Multivariate analyses were performed to explore associations between baseline variables and long‐term treatment response. Results: A total of 454 patients (91% female, mean age 48) were analyzed, with follow‐up at 2 years ( n = 454), 3 years ( n = 135), and 4 years ( n = 17). Treatments included erenumab (39%), galcanezumab (34%), and fremanezumab (27%). Fifty‐seven percent maintained continuous therapy, while 43% restarted after discontinuation. Sustained reductions in MHD and MMD were observed at 2, 3, and 4 years (MHD from 20 to 6, 6, 5/MMD from 14 to 4, 4, and 2). Medication overuse decreased from 78% to 13%, 20%, and 18%. Loss of effectiveness occurred in 4.2% after 2 years. AEs appeared in 80%), leading to discontinuation in 0.4%. Multivariate analysis showed that shorter disease duration prior to anti‐CGRP initiation, earlier anti‐CGRP initiation, and greater MHD/MMD reduction at 6 months were associated with better long‐term outcomes. Conclusions: Anti‐CGRP mAbs demonstrate sustained long‐term safety and effectiveness, with consistent reduction in headache and migraine days and lower medication overuse. Early initiation and greater initial improvement predict better long‐term outcomes. Findings support extending therapy beyond 12–18 months, supporting optimization of clinical protocols.Keywords
Funding Information
- European Commission
This publication has 33 references indexed in Scilit:
- Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN studyCurrent Medical Research and Opinion, 2022
- Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trialBMC Neurology, 2021
- Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trialEuropean Journal of Neurology, 2021
- Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraineEmerging Topics in Life Sciences, 2020
- European headache federation consensus on the definition of resistant and refractory migraineThe Journal of Headache and Pain, 2020
- CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implicationsCephalalgia, 2019
- Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet, 2017
- Migraine prevalence, disease burden, and the need for preventive therapyNeurology, 2007
- Neuronal expression and regulation of CGRP promoter activity following viral gene transfer into cultured trigeminal ganglia neuronsBrain Research, 2004
- A six-item short-form survey for measuring headache impact: The HIT-6™Quality of Life Research, 2003